Janssen’s Sirturo (Bedaquiline) Expands Indication to Include Adolescents with MDR-TB
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has announced that the National...
Drug
Chongqing Zhifei Biological Launches Phase I Clinical Trial for Group B Meningococcal Vaccine
Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has announced the commencement of a Phase I...
Chipscreen Pharmaceutical’s Epidaza Granted Priority Status for DLBCL Treatment in China
The Center for Drug Evaluation (CDE) website has announced that Shenzhen Chipscreen Biosciences Co., Ltd’s...
HutchMed’s Elunate-Tyvyt Combo Receives Breakthrough Therapy Designation in China for Endometrial Cancer
HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) has announced that the combination of Elunate (fruquintinib)...
Kintor Pharmaceutical Initiates Long-Term Safety Trial for Androgenetic Alopecia Treatment KX-826
China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced the start of the long-term safety trial...
Shanghai Junshi Biosciences’ Tuoyi Receives NMPA Review for ES-SCLC Treatment
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced that the National Medical...
Qihan Biotech’s QN-019a Receives Clinical Clearance for Gene-Edited iPSC-Derived Cell Therapy in China
Hangzhou Qihan Biotech Co., Ltd., a leading specialist in xenotransplantation based in China, has announced...
Antengene Initiates Phase I ERASER Study for ATG-017 in Combination with Nivolumab
China-based biopharmaceutical company Antengene Corp., Ltd (HKG: 6996) has announced the first patient dosing in...
Sichuan Huiyu Pharmaceutical’s KRAS G12C Drug HYP-2090PTSA Accepted for NMPA Review
Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a China-based pharmaceutical company, has announced that the...
Sanofi and AstraZeneca Receive FDA Approval for RSV Prevention Treatment Beyfortus
France-based Sanofi (NASDAQ: SNY) has announced that it, along with AstraZeneca (AZ; NASDAQ: AZN), has...
NMPA Releases 70th Batch of Reference Drugs for Generic Quality Consistency Evaluation
The National Medical Products Administration (NMPA) has released the 70th batch of reference drugs for...
Mabwell Bioscience’s 7MW3711 ADC for B7-H3 Gets Clinical Trial Approval in China
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced receiving clinical...
Bayer’s Kerendia Officially Launched in China for Type 2 Diabetes-Related CKD
German pharmaceutical giant Bayer’s (ETR: BAYN) Kerendia (finerenone), the first nonsteroidal, selective mineralocorticoid receptor (MR)...
Shenzhen Salubris Pharmaceuticals Receives FDA Clearance for SAL0119 Clinical Trial
Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294), a Chinese pharmaceutical company, has announced that it...
Bio-Thera Solutions Receives NMPA Approval for CTLA-4 and PD-1 Inhibitor Combo Study
China-based Bio-Thera Solutions Ltd (SHA: 688177) has announced that it has received approval from China’s...
Shanghai Pharmaceuticals Gets NMPA Green Light for Recombinant Human Adenovirus Type 5 Trial
Shanghai Pharmaceuticals (HKG: 2607; SHA: 601607), a leading pharmaceutical company in China, has announced that...
Nanjing Immunophage Biotech’s IPG11406 Approved for SLE Clinical Trial in China
Nanjing Immunophage Biotech Co., Ltd, a China-based biotechnology company, has announced that it has received...
Zai Lab and argenx Report Positive Preliminary Results from Vyvgart Hytrulo CIDP Study
China-based Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) and its Netherlands-based partner argenx SE (NASDAQ:...
Janssen’s Rybrevant Meets Primary Endpoint in Phase III NSCLC Study
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has announced positive results from...
Antengene Corp., Ltd Receives Hong Kong NDA Approval for Xpovio in Relapsed Multiple Myeloma
China-based biopharmaceutical company Antengene Corp., Ltd (HKG: 6996) has announced receiving New Drug Application (NDA)...